| Product Includes | Product # | Quantity | Mol. Wt | Isotype/Source |
|---|---|---|---|---|
| MyD88 (D80F5) Rabbit mAb | 4283 | 20 µl | 33 kDa | Rabbit IgG |
| IRAK1 (D51G7) Rabbit mAb | 4504 | 20 µl | 78-105 kDa | Rabbit IgG |
| IRAK2 Antibody | 4367 | 20 µl | 62 kDa | Rabbit |
| IRAK4 Antibody | 4363 | 20 µl | 55 kDa | Rabbit |
| Phospho-IRAK4 (Thr345/Ser346) (D6D7) Rabbit mAb | 11927 | 20 µl | 55 kDa | Rabbit IgG |
| TRAF6 (E2K9D) Rabbit mAb | 67591 | 20 µl | 60 kDa | Rabbit IgG |
| TBK1/NAK (E8I3G) Rabbit mAb | 38066 | 20 µl | 84 kDa | Rabbit IgG |
| Phospho-TBK1/NAK (Ser172) (D52C2) XP® Rabbit mAb | 5483 | 20 µl | 84 kDa | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody | 7074 | 100 µl | Goat |
Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.
Description
The Myddosome Complex Antibody Sampler Kit provides an economical means of detecting the components of the myddosome complex using phospho-specific and control antibodies. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Storage
Background
Toll-like receptors (TLRs) are a large family of so-called pattern recognition receptors (PRRs) that detect pathogen associated molecular patterns (PAMPs) and danger associated molecular patterns (DAMPs) (1,2). Upon activation, TLRs initiate two main signaling pathways through their C-terminal cytoplasmic Toll/Il-1 receptor (TIR) domain that couples with TIR domain-containing adaptors MyD88 and TRIF. The MyD88-dependent pathway is initiated by the formation of a large oligomeric protein complex termed myddosome. Myddosome is one of so-called supramolecular organizing centers (SMOCs), a signaling organelle that is common for PRRs in the innate immune system. Myddosome formation promotes IRAK4 activation, which in turn activates IRAK1 and later, IRAK2. TRAF6 is then recruited and activated through the binding sites within IRAKs. Activated TRAF6 is released to the cytosol and triggers the IKK complex to activate the NF-κB pathway to mediate the expression of pro-inflammatory cytokines and chemokines (3-7). Recently, it was also found that TBK1 is recruited to the myddosome complex and activated to induce aerobic glycolysis (8).
- Behzadi, P. et al. (2021) J Immunol Res 2021, 9914854.
- Aluri, J. et al. (2021) Cells 10, 1374. doi: 10.3390/cells10061374.
- De Nardo, D. (2015) Cytokine 74, 181-9.
- Latty, S.L. et al. (2018) Elife 7:e31377. doi: 10.7554/eLife.31377.
- De Nardo, D. et al. (2018) J Biol Chem 293, 15195-15207.
- Balka, K.R. and De Nardo, D. (2019) J Leukoc Biol 105, 339-351.
- Gold, J.J. et al. (1988) Biosystems 21, 403-15.
- Tan, Y. and Kagan, J.C. (2019) Cell 177, 384-398.e11.
Background References
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
